Advertisement
AMRN vs VCEL
To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is AMRN is a Hold and VCEL is a StrongBuy.
AMRN's Stochastic Oscillator remains in oversold zone for 19 days
The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an uptrend is expected.
Technical Analysis (Indicators)
Bullish Trend Analysis
The RSI Indicator shows that the ticker has stayed in the oversold zone for 15 days. The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an Uptrend is expected.
Following a +0.69% 3-day Advance, the price is estimated to grow further. Considering data from situations where AMRN advanced for three days, in 184 of 251 cases, the price rose further within the following month. The odds of a continued upward trend are 73%.
AMRN may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
Bearish Trend Analysis
The Momentum Indicator moved below the 0 level on September 18, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on AMRN as a result. In 70 of 85 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 82%.
The Moving Average Convergence Divergence Histogram (MACD) for AMRN turned negative on September 18, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 53 similar instances when the indicator turned negative. In 45 of the 53 cases the stock turned lower in the days that followed. This puts the odds of success at 85%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where AMRN declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 85%.
The Aroon Indicator for AMRN entered a downward trend on October 21, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Fundamental Analysis (Ratings)
The Tickeron PE Growth Rating for this company is 25 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Valuation Rating of 71 (best 1 - 100 worst) indicates that the company is slightly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (0.548) is normal, around the industry mean (-3.196). P/E Ratio (-9.592) is within average values for comparable stocks, (21.213). Projected Growth (PEG Ratio) (3.220) is also within normal values, averaging (5.738). Dividend Yield (0.000) settles around the average of (0.041) among similar stocks. P/S Ratio (1.554) is also within normal values, averaging (4.033).
The Tickeron Price Growth Rating for this company is 78 (best 1 - 100 worst), indicating slightly worse than average price growth. AMRN’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron SMR rating for this company is 92 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. AMRN’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 61, placing this stock worse than average.
VCEL in upward trend: price rose above 50-day moving average on October 21, 2026
VCEL moved above its 50-day moving average on October 21, 2026 date and that indicates a change from a downward trend to an upward trend. In 49 of 60 similar past instances, the stock price increased further within the following month. The odds of a continued upward trend are 82%.
Technical Analysis (Indicators)
Bullish Trend Analysis
The Momentum Indicator moved above the 0 level on October 20, 2026. You may want to consider a long position or call options on VCEL as a result. In 73 of 99 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 74%.
The Moving Average Convergence Divergence (MACD) for VCEL just turned positive on September 16, 2026. Looking at past instances where VCEL's MACD turned positive, the stock continued to rise in 39 of 53 cases over the following month. The odds of a continued upward trend are 74%.
Following a +1.41% 3-day Advance, the price is estimated to grow further. Considering data from situations where VCEL advanced for three days, in 214 of 278 cases, the price rose further within the following month. The odds of a continued upward trend are 77%.
The Aroon Indicator entered an Uptrend today. In 156 of 225 cases where VCEL Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are 69%.
Bearish Trend Analysis
The Stochastic Oscillator may be shifting from an upward trend to a downward trend. In 53 of 67 cases where VCEL's Stochastic Oscillator exited the overbought zone, the price fell further within the following month. The odds of a continued downward trend are 79%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where VCEL declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 72%.
VCEL broke above its upper Bollinger Band on October 05, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
Fundamental Analysis (Ratings)
The Tickeron Price Growth Rating for this company is 47 (best 1 - 100 worst), indicating steady price growth. VCEL’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Seasonality Score of 50 (best 1 - 100 worst) indicates that the company is fair valued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.
The Tickeron SMR rating for this company is 78 (best 1 - 100 worst), indicating slightly better than average sales and a considerably profitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron PE Growth Rating for this company is 94 (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Valuation Rating of 96 (best 1 - 100 worst) indicates that the company is significantly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (5.665) is normal, around the industry mean (2.988). VCEL has a moderately high P/E Ratio (83.551) as compared to the industry average of (-1.158). Projected Growth (PEG Ratio) (0.040) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (123.903) among similar stocks. P/S Ratio (6.887) is also within normal values, averaging (438.009).
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. VCEL’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock worse than average.
AMRN | VCEL | ||
|---|---|---|---|
OUTLOOK RATING 1..100 | 71 | 33 | |
VALUATION overvalued / fair valued / undervalued 1..100 | 71 Overvalued | 96 Overvalued | |
PROFIT vs RISK RATING 1..100 | 100 | 100 | |
SMR RATING 1..100 | 92 | 78 | |
PRICE GROWTH RATING 1..100 | 78 | 47 | |
P/E GROWTH RATING 1..100 | 25 | 94 | |
SEASONALITY SCORE 1..100 | 50 | 50 |
Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.
AMRN's Valuation (71) in the Pharmaceuticals Other industry is in the same range as VCEL (96) in the Medical Specialties industry. This means that AMRN’s stock grew similarly to VCEL’s over the last 12 months.
AMRN's Profit vs Risk Rating (100) in the Pharmaceuticals Other industry is in the same range as VCEL (100) in the Medical Specialties industry. This means that AMRN’s stock grew similarly to VCEL’s over the last 12 months.
VCEL's SMR Rating (78) in the Medical Specialties industry is in the same range as AMRN (92) in the Pharmaceuticals Other industry. This means that VCEL’s stock grew similarly to AMRN’s over the last 12 months.
VCEL's Price Growth Rating (47) in the Medical Specialties industry is in the same range as AMRN (78) in the Pharmaceuticals Other industry. This means that VCEL’s stock grew similarly to AMRN’s over the last 12 months.
AMRN's P/E Growth Rating (25) in the Pharmaceuticals Other industry is significantly better than the same rating for VCEL (94) in the Medical Specialties industry. This means that AMRN’s stock grew significantly faster than VCEL’s over the last 12 months.
| AMRN | VCEL | |
|---|---|---|
| RSI ODDS (%) | 2 days ago 76% | N/A |
| Stochastic ODDS (%) | 2 days ago 82% | 2 days ago 79% |
| Momentum ODDS (%) | 3 days ago 82% | 2 days ago 74% |
| MACD ODDS (%) | 3 days ago 85% | 7 days ago 74% |
| TrendWeek ODDS (%) | 2 days ago 86% | 2 days ago 78% |
| TrendMonth ODDS (%) | 2 days ago 85% | 2 days ago 77% |
| Advances ODDS (%) | 9 days ago 73% | 2 days ago 77% |
| Declines ODDS (%) | 7 days ago 85% | 9 days ago 72% |
| BollingerBands ODDS (%) | 2 days ago 82% | 2 days ago 80% |
| Aroon ODDS (%) | 2 days ago 78% | 2 days ago 69% |
Long-Term Analysis
It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is overvalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).
AMRN’s FA Score shows that 1 FA rating(s) are green while VCEL’s FA Score has 0 green FA rating(s).
- AMRN’s FA Score: 1 green, 4 red.
- VCEL’s FA Score: 0 green, 5 red.
Short-Term Analysis
It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.
If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.
AMRN’s TA Score shows that 4 TA indicator(s) are bullish while VCEL’s TA Score has 5 bullish TA indicator(s).
- AMRN’s TA Score: 4 bullish, 4 bearish.
- VCEL’s TA Score: 5 bullish, 3 bearish.
Price Growth
AMRN (@Pharmaceuticals: Major) experienced а -0.86% price change this week, while VCEL (@Biotechnology) price change was +1.71% for the same time period.
The average weekly price growth across all stocks in the @Pharmaceuticals: Major industry was +0.73%. For the same industry, the average monthly price growth was -4.97%, and the average quarterly price growth was +5.45%.
The average weekly price growth across all stocks in the @Biotechnology industry was -1.02%. For the same industry, the average monthly price growth was -18.10%, and the average quarterly price growth was -15.28%.
Reported Earning Dates
AMRN is expected to report earnings on Nov 04, 2026.
VCEL is expected to report earnings on Nov 05, 2026.
Industries' Descriptions
@Pharmaceuticals: Major (+0.73% weekly)The Major Pharmaceuticals industry includes companies that are involved in various processes of creating drugs to treat/prevent diseases. These companies engage in research, testing and manufacturing, as well as the distribution of pharmaceuticals into markets. Johnson & Johnson, Merck & Co., Inc., Pfizer Inc. and Novartis are among the largest companies in this category.
@Biotechnology (-1.02% weekly)Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.
Advertisement
VCEL and
Correlation & Price change
A.I.dvisor indicates that over the last year, VCEL has been loosely correlated with VCYT. These tickers have moved in lockstep 52% of the time. This A.I.-generated data suggests there is some statistical probability that if VCEL jumps, then VCYT could also see price increases.
| Ticker / NAME | Correlation To VCEL | 1D Price Change % | ||
|---|---|---|---|---|
| VCEL | 100% | +0.89% | ||
| VCYT - VCEL | 52% Loosely correlated | +3.19% | ||
| AXON - VCEL | 38% Loosely correlated | +2.54% | ||
| MDWD - VCEL | 36% Loosely correlated | N/A | ||
| AMRN - VCEL | 36% Loosely correlated | +0.26% | ||
| CRSP - VCEL | 34% Loosely correlated | +1.24% | ||
More | ||||
| 1 Day | |||
|---|---|---|---|
| ETFs / NAME | Price $ | Chg $ | Chg % |
| TOV | 32.61 | 0.21 | +0.66% |
| JLens 500 Jewish Advocacy U.S. ETF | |||
| IAUG | 30.28 | 0.09 | +0.30% |
| Innovator International Developed Power Buffer ETF August (IAUG) | |||
| JBK | 25.75 | N/A | N/A |
| Lehman ABS Corp | |||
| EWS | 31.32 | -0.01 | -0.03% |
| iShares MSCI Singapore ETF (EWS) | |||
| RDYY | 14.94 | -0.21 | -1.39% |
| YieldMax RDDT Option Income Strategy ETF (RDYY) | |||